Maria Antonia Wijdeven

This inventor holds 21 USPTO granted patents and 17 published patent applications and 10 EPO patents, primarily in Bioconjugate Chemistry. Top assignee: Synaffix B.v.. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Maria Antonia Wijdeven. Retrieved from https://idiyas.com/inventor/maria-antonia-wijdeven

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 17)

% Patents Active = 100.0

EPO Patents = 10 (Patent Applications = 30)

Average Co-Inventor Count = 4.5

ph-index = 4

Forward Citations = 129(Granted Patents)

Location History:

HR Lent, NL (2022)
Lent, NL (2016 - 2024)
Wijchen, NL (2020 - 2024)

Company Filing History:

21 out of 32

Synaffix B.v.

patents

Years Active: 2016-2025

Loading Chart...

Areas of Expertise:

Antibody-Conjugates

Sulfamide Linkers

Glycoprotein Modification

Bioconjugates

Therapeutic Index

Enzymes

Glycosyltransferase

Chemical Synthesis

Tumor Targeting

Protein-Conjugates

Cycloaddition

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12397063 - Antibody-conjugates for targeting of tumours expressing Trop-2 (2025-08-26),

2. 12281135 - Synthesis of 6-azido-6-deoxy-2-n-acetyl-hexosamine-nucleoside diphosphate (2025-04-21),

3. 12194107 - Modified antibody, antibody-conjugate and process for the preparation thereof (2025-01-14),

4. 12049656 - Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a β(1,4)-n-acetylgalactosaminyltransferase (2024-07-30),

5. 11957763 - Sulfamide linkers for use in bioconjugates (2024-04-16),

6. 11951175 - Bioconjugates containing sulfamide linkers for use in treatment (2024-04-09),

7. 11850286 - Sulfamide linker, conjugates thereof, and methods of preparation (2023-12-26),

8. 11713453 - Enzymes for trimming of glycoproteins (2023-08-01),

9. 11590239 - Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates (2023-02-28),

10. 11338043 - Antibody-conjugates with improved therapeutic index for targeting HER2 tumours and method for improving therapeutic index of antibody-conjugates (2022-05-24),

11. 11299759 - Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a β(1,4)-n-acetylgalactosaminyltransferase (2022-04-12),

12. 10874746 - Sulfamide linkers for use in bioconjugates (2020-12-29),

13. 10858641 - Enzymes for trimming of glycoproteins (2020-12-08),

14. 10792369 - Sulfamide linker, conjugates thereof, and methods of preparation (2020-10-06),

15. 10745488 - Modified antibody, antibody-conjugate and process for the preparation thereof (2020-08-18),

Title: Maria Antonia Wijdeven: Innovator in Antibody Modification

Introduction

Maria Antonia Wijdeven, a distinguished inventor based in Lent, Netherlands, has made significant contributions to the field of biochemistry with 19 patents to her name. Her innovative research focuses on modified antibodies and processes that enhance their utility in medicine.

Latest Patents

Among her latest patents, one notable invention is titled "Modified antibody, antibody-conjugate and process for the preparation thereof." This invention relates to an antibody featuring a GlcNAc-S(A) substituent, where S(A) includes functional groups such as azido, keto, or alkynyl groups, which are essential for enhancing the antibody's effectiveness. Moreover, her invention encompasses an antibody-conjugate formula that incorporates various molecules of interest, contributing significantly to therapeutic applications. Additionally, Wijdeven has developed a process for the modification of glycoproteins using a glycosyltransferase derived from β(1,4)-N-acetylgalactosaminyltransferase, enabling enzymatic alterations that further advance glycoprotein functionality.

Career Highlights

Maria Antonia Wijdeven currently works at Synaffix B.V., a company dedicated to developing innovative antibody-drug conjugates. Her expertise in modifying antibodies and glycoproteins has positioned her as a leading figure in her field, contributing to advancements with potential pharmaceutical applications. With a robust catalog of patents, she demonstrates profound knowledge and creativity in biochemistry and molecular biology.

Collaborations

Throughout her career, Wijdeven has collaborated with esteemed colleagues such as Floris Louis Van Delft and Sander Sebastiaan Van Berkel. These partnerships have fostered a dynamic research environment, amplifying their collective contributions to science and innovation.

Conclusion

Maria Antonia Wijdeven stands out as a prominent inventor in the realm of biochemistry. Her inventions, centered on antibody modification and glycoprotein processes, promise to pave the way for novel medical interventions. With continued collaborations and an impressive patent portfolio, Wijdeven is poised to make even more impactful strides in her field.

Profile summary based on public USPTO records.